Skip to content

Tectonic Therapeutics TECX Additional Paid-In Capital

Additional Paid-In Capital at other companies

ALN
Alnylam PharmaceuticalsALNY
$7.6B+1.3%
Septerna, Inc. logo
Septerna, Inc.SEPN
$554.87M+2.8%
Regenxbio logo
RegenxbioRGNX
$1.24B+3.1%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$174.65M+26.4%
Opko Health logo
Opko HealthOPK
$3.57B+2.5%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$6.67B+1.5%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's additional paid-in capital?
Tectonic Therapeutics (TECX) reported additional paid-in capital of $478.39M in Q1 2026.
How has Tectonic Therapeutics's additional paid-in capital changed year-over-year?
Tectonic Therapeutics's additional paid-in capital increased by 2.8% year-over-year, from $465.52M to $478.39M.
What is the long-term trend for Tectonic Therapeutics's additional paid-in capital?
Over 5 years (2020 to 2025), Tectonic Therapeutics's additional paid-in capital has grown at a -1.8% compound annual growth rate (CAGR), from $518.76M to $474.16M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.